Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Clinical Partners, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,097,312

351 payments

Through program year 2024, Clinical Partners, LLC is reported as receiving $1,097,312 in research payments, across 351 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $44,012 8
2023 Research $81,106 17
2022 Research $128,829 22
2021 Research $321,352 137
2020 Research $200,186 60
2019 Research $321,827 107

Breakdown

Who paid Research payments · program years 2019–2024
  1. Ucb SA $650,840 176 payments
  2. AbbVie, Inc. $175,137 73 payments
  3. Celgene Corporation $97,282 7 payments
  4. Amgen Inc. $94,391 13 payments
  5. Vanda Pharmaceuticals Inc. $31,704 16 payments
  6. Arcutis Biotherapeutics, Inc. $13,177 11 payments
  7. VYNE Pharmaceuticals Inc. $13,004 31 payments
  8. AstraZeneca Pharmaceuticals LP $10,760 4 payments
  9. Dr.Reddy's Laboratories,Inc. $10,282 10 payments
  10. Sun Pharmaceutical Industries Inc. $652 9 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $182,336 67 payments
  2. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $133,509 30 payments
  3. A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $117,435 30 payments
  4. ABP 654 P3 PsO Study $83,864 5 payments
  5. A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $74,869 22 payments
  6. A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) $74,091 2 payments
  7. M16-045 $67,443 25 payments
  8. A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $65,852 9 payments
  9. M16-813 $62,161 14 payments
  10. A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis $34,851 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record